America’s biopharmaceutical research companies currently are developing 221 innovative new medicines to help the nearly 26 million patients in the United States affected by diabetes. These medicines in development – all in either clinical trials or under review by the Food and Drug Administration (FDA) – include 32 for type 1 diabetes, 130 for type 2 and 64 for diabetes-related conditions, according to a new report released by the Pharmaceutical Research and Manufacturers of America (PhRMA).